Both anaemia and blood transfusion are associated with poor outcomes in the neurosurgical population. Based on the available literature, the optimal haemoglobin concentration for neurologically injured patients appears to be in the range of 9.0e10.0 g dl À1 , although the individual risks and benefits should be weighed. Several perioperative blood conservation strategies have been used successfully in neurosurgery, including correction of anaemia and coagulopathy, use of antifibrinolytics, and intraoperative cell salvage. Avoidance of non-steroidal anti-inflammatory drugs and starchcontaining solutions is recommended given the potential for platelet dysfunction.
The development of modern neurosurgery was facilitated by the evolution of general anaesthesia, intravenous fluid management, aseptic technique, and advances in neurosurgical haemostasis in the 19 th and 20 th centuries. 1 In 1904, pioneering American neurosurgeon Harvey Cushing described the use of a pneumatic tourniquet to reduce intraoperative bleeding from the scalp. 2 He went on to describe the utility of high frequency electrocautery in the excision of previously inaccessible intracranial tumours 3 and the use of operative cell salvage and return of autologous blood. 4 In 1946, Gardner provided an account of induced hypotension to reduce blood loss and improve neurosurgical operating conditions. 5 Cushing's landmark publication in 1911 provided a summary of neurosurgical haemostasis techniques and highlighted his appreciation for the importance of a bloodless field to achieve surgical precision, avoid haemorrhagic shock, and prevent complications of anaemia. 6 Taken for granted today, these tenets were radical in the early 20 th century and not universally accepted. In particular, Cushing's recognition of the association between anaemia and poor neurosurgical outcome was ahead of its time. Although an accumulating body of evidence now supports his observation, many questions regarding haemostasis and anaemia in the neurosurgical population remain. This paper aims to review the epidemiology and clinical outcomes associated with anaemia and blood transfusion, and identify perioperative blood conservation strategies to minimise blood loss in patients undergoing intracranial neurosurgical procedures.
What is the significance of anaemia in the neurosurgical population?
Although it constitutes only 2% of total body weight, the human brain has high metabolic requirements and receives 20e25% of cardiac output (CO). Total cerebral oxygen delivery is a function of cerebral blood flow (CBF) multiplied by the oxygen content of the blood (CaO 2 ). CBF is ordinarily autoregulated over a wide range of cerebral perfusion pressures (CPP) at approximately 50 ml 100 g À1 min À1 where CPP is determined by the mean arterial pressure (MAP) minus the cerebral venous pressure (or intracranial pressure, whichever is higher). Outside the normal physiological limits of CPP (~60e160 mm Hg), CBF is linearly dependent upon MAP. During periods of acute anaemia (reduced CaO 2 ), oxygen delivery is maintained via compensatory cardiovascular and cerebrovascular changes including an increase in CO, preferential distribution of CO to the cerebral circulation, increased cerebral oxygen extraction, and, importantly, an increase in CBF secondary to active cerebral vasodilatation. 7 In the setting of normovolaemic anaemia, reduced blood viscosity is a major determinant of increased CO through enhanced preload and reduced afterload. 8 Reduced viscosity may also improve the flow characteristics (i.e. rheology) of blood particularly through areas of cerebral vascular stenoses. However, these compensatory mechanisms have limitations. As cerebral oxygen utilisation becomes supply dependent, anaemia may contribute to reduced cerebral oxygen delivery and a secondary hypoxic insult to the injured brain. In healthy volunteers, anaemia-induced cognitive dysfunction is evident at haemoglobin (Hb) concentrations between 5.0 and 6.0 g dl
Following acute brain injury, impaired autoregulatory mechanisms may allow anaemia-induced cerebral dysfunction and injury at higher Hb thresholds. In a recent retrospective cohort study of patients with severe traumatic brain injury (TBI), the amount of time spent with an Hb concentration !9.0 g dl
À1
was associated with improved neurological outcome at 6 months. 10 Similarly, in a previous cohort of patients with severe TBI, the association of anaemia (Hb<9.0 g dl
) with low brain tissue oxygen tension (<20 mm Hg) was a risk factor for poor neurological outcome. 11 In patients with subarachnoid haemorrhage (SAH), a reduction in red cell volume precedes neurological deterioration. 12 An Hb threshold >11 g dl À1 is associated with a reduced incidence of symptomatic cerebral vasospasm 13 and more favourable neurological outcome. 14 At higher Hb concentrations, however, the benefit of increased oxygen carrying capacity may be offset by increases in blood viscosity and reduced CBF. 15 The incidence of anaemia in neurosurgical procedures varies depending on the population and surgery. Data from the National Surgical Quality Improvement Program reveal that the incidence of moderate to severe anaemia (i.e. haematocrit <30%) in elective cranial surgery is 2.7%. 16, 17 In critically-ill neurosurgical patient populations, however, the incidence increases; at least 50% of patients with TBI 18 and 47% of patients after SAH are anaemic. 19 In the critically-ill population, anaemia may be multifactorial resulting from systemic inflammatory-mediated suppression of haematopoiesis, frequent phlebotomy, haemorrhage, and haemodynamic resuscitation-induced haemodilution. In the context of SAH, anaemia may result from deliberate hypervolaemia and haemodilution for the prevention and treatment of vasospasm. A growing body of evidence in neurosurgical patients supports anaemia as an independent predictor of cerebral vasospasm, medical complications, poor neurological outcome, and increased mortality. 14, 17, 20, 21 What is the significance of transfusion in the neurosurgical population?
In the setting of anaemia, transfusion of blood products can rapidly increase Hb concentrations and oxygen delivery. Overall, cohort studies including all types of neurosurgical procedures have reported a rate of allogeneic transfusion of 1.7e5.4%. 22, 23 However, the reported incidence of transfusion for specific patient populations undergoing intracranial neurosurgery ranges from 10 to 95% with a much higher incidence among paediatric patients undergoing craniosynostosis surgery and cranial vault reconstruction (Table 1 ). In the paediatric population undergoing brain tumour resection, age <4 years, duration of surgery >270 min, and a preoperative Hb concentration <12.2 g dl À1 were independent predictors of allogeneic blood transfusion. 24 In the context of isolated TBI, the presence of acute traumatic coagulopathy increased the risk of transfusion by 41% and increased hospital length of stay and mortality. 25 In aneurysmal SAH, administration of packed red blood cells is strongly related to intraoperative aneurysm rupture 26 and may be as high as 25%. 27 The rate of transfusion also varies depending on the procedure, from 10% in complex skull base neurosurgical procedures 28 to 36% in patients with TBI 29 and as high as 45% in paediatric craniosynostosis surgery. 30 In the latter instance, risk factors for large volume blood loss and transfusion include syndromic craniosynostosis, pansynostosis, age <18 months, and longer duration of procedure. 31 A recent multicentre observational study of children undergoing complex cranial vault reconstruction in North America demonstrated that 95% of infants aged <24 months and 79% of children aged >24 months underwent perioperative allogeneic blood transfusion. 32 Future strategies to reduce transfusion should focus on the identification and mitigation of modifiable risk factors in these populations. Paradoxically, while the definitive management of anaemia-induced organ dysfunction remains the transfusion of allogeneic red blood cells, transfusion itself confers an increased risk of morbidity and mortality.
33e36 Changes in immunomodulation, infectious and allergic complications, and transfusion associated lung injury and circulatory overload are all potential pathological consequences of transfusion. These complications result in an increased risk of respiratory failure, prolonged intubation, acute respiratory distress syndrome, wound infection, sepsis, cardiac events, increased hospital length of stay and death. In the setting of TBI, a clinical trial comparing Hb transfusion thresholds of 7.0 g dl À1 vs 10.0 g dl À1 revealed an increased risk of thromboembolic events in the latter with no significant improvement in neurological outcome. 37 Further analysis of this data demonstrated a more than two-fold increase in the risk of progressive haemorrhagic injury with a Hb transfusion threshold >10.0 g dl À1 when compared with a more restrictive threshold (i.e. 7.0 g dl
. 38 In patients undergoing open neurosurgical intervention for intracranial aneurysm, perioperative blood transfusion was shown to be an independent risk factor for major morbid complications. 39 Unfortunately, the optimal trigger for Hb transfusion in neurosurgical populations remains elusive and the relative risks and benefits of anaemia and transfusion must be weighed ( Fig. 1 ). Current recommendations vary amongst clinician specialty, procedure, and severity of the underlying brain injury. 40 When surveyed, neurosurgeons recommended a higher Hb threshold for transfusion following TBI in the setting of both normal and elevated ICP as compared with trauma surgeons and intensivists. Although strict Hb transfusion triggers for neurologically injured patients remain unclear, the mitigation of cerebral ischaemia is likely to require a higher threshold than in the general critically-ill patient population where a restrictive transfusion strategy is often advocated. 41 Based on the available evidence, the minimum acceptable Hb concentration for neurologically injured patients would appear to be in the range of 9.0e10.0 g dl À1 , recognising that higher thresholds may be associated with adverse outcomes such as thrombosis or haemorrhagic progression. Although both anaemia and allogeneic blood transfusion are associated with worse clinical outcomes in neurologically injured patients, these variables are either reflective of increased severity of injury or a result of transfusion in and of itself and active blood conservation should be considered whenever possible.
What strategies are effective to minimise anaemia and transfusion in neurosurgical patients?
Perioperative blood conservation strategies in intracranial neurosurgery are summarised in Figure 2 with the evidence supporting each strategy summarised in Table 2 . Appropriate blood conservation should include the identification and correction of underlying coagulopathy including withholding of anticoagulation as appropriate. As discussed above, the presence of acute traumatic coagulopathy in TBI is associated with poorer outcomes and should be identified and definitively managed in this patient population. 25 The importance of correction of coagulopathy is illustrated by the population of patients with atrial fibrillation taking oral anticoagulation who present with intracranial haemorrhage (ICH). A recent retrospective cohort study evaluating haematoma enlargement in relation to international normalised ratio (INR) and blood pressure in the setting of ICH concluded that reversal of INR to <1.3 within 4 h of admission and systolic blood pressure to <160 mm Hg at 4 h lowered the rate of haematoma enlargement. 42 These data also suggested that INR reversal was greater with prothrombin complexes as compared with fresh frozen plasma, although the authors note that the sample size was too small to draw firm conclusions. Novel oral anticoagulants (e.g. dabigatran, rivaroxaban) are rapidly replacing warfarin in the setting of stroke prevention in atrial fibrillation but, with the exception of dabigatran, these agents currently have no specific reversal agents and are challenging to manage in the urgent perioperative setting. 43 The Neurocritical Care
Society in conjunction with the Society of Critical Care Medicine has developed evidence-based guidelines for the reversal of antithrombotic agents, including the newer oral anticoagulants in the setting of ICH (Fig. 3) . 44 Avoidance of pharmacological disruption of coagulation intraoperatively is also prudent. Non-steroidal anti-inflammatory drugs (NSAIDs), such as flurbiprofen, have potent antiplatelet effects and are associated with an increased risk of intracranial haematoma following intracranial procedures. 45 NSAIDs should be avoided during intracranial procedures. Similarly, synthetic starch solutions inhibit platelet function 46 and recent evidence demonstrated that their use results in alteration in rotational thromboelastography parameters in elective brain tumour resection. 47 Nevertheless, a retrospective cohort study failed to demonstrate an association between post-craniotomy haematoma and the use of hydroxyethyl starch solutions, 45 and further research is needed to clarify their safety in this population. In contrast, certain neurosurgical populations may benefit from anticoagulation, such as those patients with symptomatic carotid stenosis. A prospective audit in patients with symptomatic internal carotid stenoses (50e99%) found a reduction in recurrent neurological events without increasing the risk of major perioperative bleeding in those who received dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel before carotid endarterectomy. 48 Low-dose ASA (<325 mg) is associated with better short-term outcomes than highdose ASA (>650 mg) in these patients. 49 The maintenance or did not find any difference in thrombotic complications. 37, 52 In elective surgery, preoperative autologous donation (PAD) may reduce the need for allogeneic blood transfusion in certain patient populations including those undergoing cardiac surgery with cardiopulmonary bypass. 54 In intracranial neurosurgery, however, the evidence for PAD is limited. A retrospective matched cohort study of neurosurgical patients receiving EPO in the presence and absence of PAD found increased perioperative anaemia and no difference in exposure to allogeneic blood transfusion in the presence of PAD. 55 Overall, PAD cannot currently be recommended as a blood conservation technique for neurosurgical patients. Acute normovolaemic haemodilution (ANH), another blood conservation technique involving autologous blood withdrawal currently advocated by the ASA practice guidelines on perioperative blood management, 56 also has limited evidence in neurosurgery. A small prospective, randomised controlled study on patients undergoing elective intracranial meningioma resection found a significant reduction in the amount of allogeneic blood transfused to patients following ANH as compared with control. 57 A more recent prospective, nonrandomised trial on the use of ANH during intracranial neurosurgery for ruptured cerebral aneurysm, however, found no significant difference between ANH and control in the number of patients requiring allogeneic blood transfusion. 58 ANH may be considered as a possible blood conservation technique in elective neurosurgical cases of otherwise healthy individuals where large volume blood loss is anticipated. Baseline Hb concentrations which permit haemodilution to a target haematocrit that will maintain adequate tissue oxygenation are required; assuming normovolaemia and adequate cardiac performance, the 'safe' lower limit is a haematocrit of approximately 20e25% and a preoperative Hb of >12 g dl À1 has been proposed. 59 Synthetic starch solutions are often cited as the preferred nonered cell containing The administration of EPO was for evaluation of potential direct neuroprotective effects and NOT for correction of anaemia. replacement fluid secondary to increased intravascular halflife but, given the antiplatelet effect of starches, crystalloids may be more favourable in the setting of neurosurgery. Contraindications to ANH include coronary artery disease, hypovolaemic or hypervolaemic states (i.e. liver cirrhosis), increased oxygen requirements (i.e. sepsis, fever), underlying coagulopathy, and any major cardiac, respiratory, or renal disease. The use of antifibrinolytic agents such as tranexamic acid (TXA) reduces allogeneic blood transfusion requirements in multiple surgical patient populations such as joint arthroplasty, cardiac, spine, and trauma. 60 Data from the CRASH-2
Intracranial Bleeding Study, a nested randomised controlled trial in trauma patients with reduced Glasgow Coma Scale and ICH, suggested a reduction in ICH size and lower mortality in patients randomised to TXA compared with control, although these results did not achieve statistical significance. 61 The CRASH-3 trail was thus designed to investigate the effect of TXA on mortality and disability in isolated TBI with results expected in the near future. 62 Data on antifibrinolytics in neurosurgical populations other than TBI are limited. In paediatric patients undergoing craniosynostosis surgery, TXA significantly reduced blood loss and blood transfusion requirements when compared with control. 63 Similarly, in children undergoing craniosynostosis surgery and pretreated with EPO, intraoperative TXA (compared with placebo) resulted in a reduction in transfusion. 30 In a retrospective cohort study of patients undergoing complex skull base neurosurgery, those who received TXA were less likely to require a blood transfusion than those who did not. 28 In the setting of SAH, antifibrinolytics might be expected to reduce the risk of aneurysmal re-bleeding and subsequent poor neurological outcome. A recent Cochrane review of randomised controlled trials examining antifibrinolytic therapy in SAH did demonstrate a reduction in re-bleeding but found an increase in cerebral ischaemia. 64 This review has been criticised for including older studies in which TXA administration was prolonged (i.e. >10 days) and further research is anticipated. Although TXA is well-tolerated, several adverse effects must be considered such as thromboembolic complications and seizures. The use of high dose TXA in cardiac surgery is associated with an increased incidence of seizures, particularly in those with an underlying predisposition (e.g. structural brain abnormality) as might occur in the neurosurgical population. 65, 66 In skull base tumour resection, however, rates of seizures and thrombosis in patients receiving TXA were similar to those who did not receive TXA, although the overall rates were low. 28 Overall, although antifibrinolytics may be of benefit in certain neurosurgical populations such as TBI, craniosynostosis and skull base surgery, current evidence does not support the routine use of antifibrinolytic therapy in aneurysmal SAH. Intraoperative cell salvage is commonly used in surgical procedures such as cardiac, major vascular, and spine; however, the literature on the use of cell salvage for intracranial surgery is extremely sparse. An older prospective cohort study on patients undergoing elective intracranial surgery and cell salvage found mild coagulation abnormalities without significant clinical bleeding and concluded that cell salvage was safe and cost-effective. 67 Notably, this study excluded patients with malignant tumours and sepsis and no long-term followup data were reported. Possible barriers to the use of cell salvage in neurosurgery include concern over tumour dissemination in the setting of malignancy, perceived lack of need, and the unpredictable nature of major haemorrhage in this patient population. 68 However, a recent systematic review on cell salvage in spine surgery secondary to metastatic disease concluded that concern over tumour dissemination is unfounded and a leucocyte-reducing filter is recommended. 69 In the absence of sufficient data, it seems reasonable to conclude that cell salvage should be available in intracranial surgery cases when large volume blood loss is anticipated such as cerebral aneurysm rupture or vascular meningioma resection.
The relatively recent availability of non-invasive, continuous Hb (SpHb) monitoring provides another potential perioperative blood conservation tool. A prospective cohort study comparing intraoperative SpHb monitoring with traditional intermittent blood sampling to achieve an Hb concentration !10.0 g dl À1 in elective neurosurgical patients found that SpHb monitoring influenced blood utilisation. 70 Although the percentage of patients transfused in the control and SpHb groups was similar, in those patients receiving a transfusion the use of SpHb monitoring resulted in fewer total units of blood transfused and a shorter time to transfusion (if required). The authors speculated that use of real-time SpHb monitoring allowed for earlier identification of attainment of the Hb threshold and thus avoidance of multiunit transfusions. More research is required to validate continuous Hb monitoring protocols given the concerns about the reliability of these monitors. 71 
Conclusion
It is clear that anaemia is common in critically ill, braininjured patients and that both anaemia and blood transfusion are associated with complications and poor outcomes in this population. The incidence and risk factors for transfusion are influenced by patient factors including the underlying neurological pathology yet optimal Hb concentrations in these patients are not presently well defined. A higher Hb threshold (i.e. >9.0 g dl À1 ) than that reserved for the general critically-ill patient is likely necessary to avoid the risk of secondary cerebral injury, however high thresholds (i.e. >10.0 g dl
À1
) may be associated with thrombosis or haemorrhagic progression. Blood conservation strategies in individual patients should take into account the underlying pathology and comorbid disease. Perioperatively, consideration should be given to the correction of underlying coagulopathy and anaemia, primarily through the use of iron replacement and EPO. Preoperative autologous donation is not recommended based on current evidence. Intraoperatively, acute normovolaemic haemodilution, continuous Hb monitoring, cell salvage and antifibrinolytic therapy should be considered, and NSAIDs and starch-containing resuscitation solutions should be avoided given the potential for platelet dysfunction. Transfusion in intracranial neurosurgery -995
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